For the year ending 2025-12-31, IKT had $82,729,629 increase in cash & cash equivalents over the period. -$27,799,863 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -48,259,189 |
| Depreciation | 60,499 |
| Stock-based compensation expense | 15,309,924 |
| Write-off of in-process research and development | 7,357,294 |
| Change in fair value contingent consideration | 1,373,942 |
| Non-cash accretion on marketable securities | 936,975 |
| Operating lease right of use assets | 101,437 |
| Prepaid expenses and other assets | -532,732 |
| Prepaid research and development | 1,920,685 |
| Other assets | 95,121 |
| Accounts payable | 146,827 |
| Operating lease liabilities | 110,517 |
| Accrued expenses and other current liabilities | 1,401,252 |
| Net cash used in operating activities | -27,786,464 |
| Purchases of equipment and improvements | 13,399 |
| Purchases of investments - marketable securities | 39,094,847 |
| Maturities of investments - marketable securities | 41,600,000 |
| Acquired in-process research and development | 438,624 |
| Net cash provided by (used in) investing activities | 2,053,130 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 107,617,495 |
| Issuance of common stock from exercise of stock options | 845,468 |
| Net cash provided by financing activities | 108,462,963 |
| Net increase in cash and cash equivalents | 82,729,629 |
| Cash and cash equivalents at beginning of year | 56,490,579 |
| Cash and cash equivalents at end of year | 139,220,208 |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)